Kevin Kalinsky, MD
The investigational AKT inhibitor capivasertib (AZD5363) demonstrated clinical activity in patients with AKT
-mutated cancers, suggesting the validity of tailoring treatment to tumor genes, according to findings from a phase II study that is part of the larger NCI-MATCH trial. The results were presented at the 2018 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
“Although we understand more than ever about the role of genes in different cancers, there is still a lack of evidence on using this knowledge to guide treatments and improve patient survival,” said Swanton. “Outside of a trial setting, this approach is not widely available. This study is a small but important piece of evidence and it’s part of a larger study that will help us move towards more personalized cancer treatments. This trial approach is particularly important for those with rarer cancers where we know less about which treatments are most effective and conducting patient trials is difficult."
Kalinsky K. AZD5363 in patients with tumours with AKT mutations: NCI-MATCH subprotocol EAY131-Y, a trial of the ECOG-ACRIN Cancer Research Group (EAY131-Y). In: Proceedings from the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; November 13-16, 2018; Dublin, Ireland. Abstract 001.
... to read the full story